These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38597864)

  • 21. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
    van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
    Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes.
    Stanton AM; Vaduganathan M; Chang LS; Turchin A; Januzzi JL; Aroda VR
    Curr Diab Rep; 2021 Sep; 21(10):41. PubMed ID: 34580767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of exercise training on outcomes in women with heart failure: analysis of HF-ACTION (Heart Failure-A Controlled Trial Investigating Outcomes of Exercise TraiNing) by sex.
    Piña IL; Bittner V; Clare RM; Swank A; Kao A; Safford R; Nigam A; Barnard D; Walsh MN; Ellis SJ; Keteyian SJ;
    JACC Heart Fail; 2014 Apr; 2(2):180-6. PubMed ID: 24720927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J; Frias J; Jastreboff AM; Du Y; Lou J; Gurbuz S; Thomas MK; Hartman ML; Haupt A; Milicevic Z; Coskun T
    Lancet; 2023 Aug; 402(10401):529-544. PubMed ID: 37385280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.
    Coats CJ; Pavlou M; Watkinson OT; Protonotarios A; Moss L; Hyland R; Rantell K; Pantazis AA; Tome M; McKenna WJ; Frenneaux MP; Omar R; Elliott PM
    JAMA Cardiol; 2019 Mar; 4(3):230-235. PubMed ID: 30725091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction.
    Van Tassell BW; Trankle CR; Canada JM; Carbone S; Buckley L; Kadariya D; Del Buono MG; Billingsley H; Wohlford G; Viscusi M; Oddi-Erdle C; Abouzaki NA; Dixon D; Biondi-Zoccai G; Arena R; Abbate A
    Circ Heart Fail; 2018 Aug; 11(8):e005036. PubMed ID: 30354558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
    Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
    JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rate-Adaptive Atrial Pacing for Heart Failure With Preserved Ejection Fraction: The RAPID-HF Randomized Clinical Trial.
    Reddy YNV; Koepp KE; Carter R; Win S; Jain CC; Olson TP; Johnson BD; Rea R; Redfield MM; Borlaug BA
    JAMA; 2023 Mar; 329(10):801-809. PubMed ID: 36871285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.
    Kosmala W; Rojek A; Przewlocka-Kosmala M; Wright L; Mysiak A; Marwick TH
    J Am Coll Cardiol; 2016 Oct; 68(17):1823-1834. PubMed ID: 27765184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type 2 diabetes is an independent predictor of lowered peak aerobic capacity in heart failure patients with non-reduced or reduced left ventricular ejection fraction.
    Abe T; Yokota T; Fukushima A; Kakutani N; Katayama T; Shirakawa R; Maekawa S; Nambu H; Obata Y; Yamanashi K; Nakano I; Takada S; Yokota I; Okita K; Kinugawa S; Anzai T
    Cardiovasc Diabetol; 2020 Sep; 19(1):142. PubMed ID: 32950064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial.
    Kitzman DW; Brubaker PH; Herrington DM; Morgan TM; Stewart KP; Hundley WG; Abdelhamed A; Haykowsky MJ
    J Am Coll Cardiol; 2013 Aug; 62(7):584-92. PubMed ID: 23665370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.
    Kosmala W; Holland DJ; Rojek A; Wright L; Przewlocka-Kosmala M; Marwick TH
    J Am Coll Cardiol; 2013 Oct; 62(15):1330-8. PubMed ID: 23916925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
    Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
    JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.
    Carbone S; Canada JM; Billingsley HE; Kadariya D; Dixon DL; Trankle CR; Buckley LF; Markley R; Vo C; Medina de Chazal H; Christopher S; Buzzetti R; Van Tassell BW; Abbate A
    Diabetes Obes Metab; 2018 Aug; 20(8):2014-2018. PubMed ID: 29603546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial.
    Wheeler MT; Olivotto I; Elliott PM; Saberi S; Owens AT; Maurer MS; Masri A; Sehnert AJ; Edelberg JM; Chen YM; Florea V; Malhotra R; Wang A; Oreziak A; Myers J
    JAMA Cardiol; 2023 Mar; 8(3):240-247. PubMed ID: 36652223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure.
    Guazzi M; Palermo P; Pontone G; Susini F; Agostoni P
    Am J Cardiol; 1999 Nov; 84(9):1038-43. PubMed ID: 10569660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study.
    Carbone S; Billingsley HE; Canada JM; Bressi E; Rotelli B; Kadariya D; Dixon DL; Markley R; Trankle CR; Cooke R; Rao K; B Shah K; Medina de Chazal H; Chiabrando JG; Vecchié A; Dell M; L Mihalick V; Bogaev R; Hart L; Van Tassell BW; Arena R; Celi FS; Abbate A
    Diabetes Metab Res Rev; 2020 Nov; 36(8):e3335. PubMed ID: 32415802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes.
    Nesti L; Pugliese NR; Sciuto P; De Biase N; Mazzola M; Fabiani I; Trico D; Masi S; Natali A
    Cardiovasc Diabetol; 2021 Jun; 20(1):124. PubMed ID: 34158062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.